迪哲医药预计2025年净亏损约7.7亿元

Core Viewpoint - Dige Pharmaceutical announced a projected loss for the fiscal year 2025, despite a significant increase in revenue [1] Group 1: Financial Performance - The company expects to achieve an operating revenue of approximately 800 million yuan, representing a year-on-year increase of about 122.28% [1] - The net loss attributable to the parent company's owners is estimated to be around 770 million yuan, which reflects a year-on-year decrease in loss of approximately 8.98% [1] - The net loss attributable to the parent company's owners, after excluding non-recurring gains and losses, is projected to be about 850 million yuan, showing a year-on-year decrease in loss of approximately 5.44% [1]